Abstract |
Between March 1986 and May 1988, the Southwest Oncology Group enrolled 58 previously untreated patients with limited small-cell lung cancer on a treatment program that administered high-dose cyclophosphamide (150 mg/kg) as late intensification. Treatment consisted of induction chemo- radiotherapy, (weeks 1 to 11), consolidation chemotherapy (weeks 11 to 18), and intensification (week 18). Median age was 61.5 years. Eighty-nine percent of patients had a Southwest Oncology Group (SWOG) performance status of 0-1. Twenty-one patients completed all prescribed treatments. There were seven treatment-related deaths, four as a result of intensification. Fifty-six patients are available for response analysis. Thirty-two patients achieved a complete remission (CR) (57%) and fifteen achieved a partial remission ( PR) (26%). Median survival for all patients is 11.1 months. Among the 21 patients who received intensification, nine remain alive in a CR with a median survival of 27 months. This sequence of treatments was not associated with a survival advantage for the group as a whole, possibly because of the toxicity of induction and consolidation treatment and the delayed administration of high-dose cyclophosphamide.
|
Authors | G E Goodman, J Crowley, R B Livingston, S E Rivkin, K Albain, J H McCulloch |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 9
Issue 3
Pg. 453-7
(Mar 1991)
ISSN: 0732-183X [Print] United States |
PMID | 1847967
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Etoposide
- Cyclophosphamide
- Cisplatin
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Carcinoma, Small Cell
(drug therapy, mortality, radiotherapy)
- Cisplatin
(administration & dosage)
- Combined Modality Therapy
- Cyclophosphamide
(administration & dosage)
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Etoposide
(administration & dosage)
- Female
- Humans
- Lung Neoplasms
(drug therapy, mortality, radiotherapy)
- Male
- Middle Aged
- Pilot Projects
- Prognosis
|